Nature Search

Is angiotensin system blockade indicated in the elderly?

Evidence supporting the renal benefits of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in elderly patients without proteinuria is lacking. However, until such data are available, if tolerated, these medications should continue to be used in this patient population because of their potent effect on blood pressure.

Carolyn Bauer
Matthew Abramowitz
Thomas H. Hostetter
News & Views01 Jan 2010
Nature Reviews Nephrology

Volume: 6, P: 11-12
N₂-promoted hydrodeoxygenation

Because of the high strength of N≡N bonds, N₂ is often employed as an inert gas. Now it has been shown that it can partly react to yield surface nitrogen species that facilitate C–O hydrogenolysis reactions on supported Ru catalysts.

Thomas J. Schwartz
News & Views12 Dec 2019
Nature Catalysis

Volume: 2, P: 1060-1061
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

An analysis of 24,202 critical cases of COVID-19 identifies potentially druggable targets in inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
ResearchOpen Access17 May 2023
Nature

Volume: 617, P: 764-768
Structure of a family of rat amylase genes

Raymond J. MacDonald
Michael M. Crerar
William J. Rutter
Research11 Sept 1980
Nature

Volume: 287, P: 117-122
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor

Warren J. Leonard
Joel M. Depper
Warner C. Greene
Research18 Oct 1984
Nature

Volume: 311, P: 626-631
Tracing ancient solar cycles with tree rings and radiocarbon in the first millennium BCE

An annually resolved tree ring radiocarbon record reveals the 11-year solar cycle in the first millennium BCE, improving understanding of past solar activity and enhancing radiocarbon dating accuracy.

Nicolas Brehm
Charlotte L. Pearson
Lukas Wacker
ResearchOpen Access06 Jan 2025
Nature Communications

Volume: 16, P: 1-10
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

Christos N. Papandreou
Badar Usmani
David M. Nanus
Research01 Jan 1998
Nature Medicine

Volume: 4, P: 50-57
Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

In a post-approval study including more than 17,000 patients on the safety of pulsed field ablation, a new method for treatment of atrial fibrillation, the procedure was found to have a low rate of adverse events but was associated with some unexpected rare complications that will need further study.

Emmanuel Ekanem
Petr Neuzil
Vivek Y. Reddy
ResearchOpen Access08 Jul 2024
Nature Medicine

Volume: 30, P: 2020-2029
A second update on mapping the human genetic architecture of COVID-19

Masahiro Kanai
Shea J. Andrews
Matthew Solomonson
ResearchOpen Access06 Sept 2023
Nature

Volume: 621, P: E7-E26
Adrenocortical tissue formed by transplantation of normal clones of bovine adrenocortical cells in scid mice replaces the essential functions of the animals' adrenal glands

Michael Thomas
S. Robert Northrup
Peter J. Hornsby
Research01 Sept 1997
Nature Medicine

Volume: 3, P: 978-983
Chemistry: Activating the C–H bond

J.M. Thomas
News & Views25 Apr 1985
Nature

Volume: 314, P: 669-670
An unusual mitochondrial DNA plasmid in the genus Brassica

Jeffrey D. Palmer
Clark R. Shields
Thomas J. Orton
Research24 Feb 1983
Nature

Volume: 301, P: 725-728
Erratum: Pushing the limits of targeted therapy in chronic myeloid leukaemia

Thomas O'Hare
Matthew S. Zabriskie
Michael W. Deininger
Amendments and Corrections15 Nov 2012
Nature Reviews Cancer

Volume: 12, P: 886
Human β-nerve growth factor gene sequence highly homologous to that of mouse

Axel Ullrich
Alane Gray
Thomas J. Dull
Research30 Jun 1983
Nature

Volume: 303, P: 821-825
Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial

A randomized controlled trial involving people with psychosis who hear distressing voices reported that two different forms of AVATAR therapy, an intervention where voice-hearers engage with a digital avatar representing this distressing voice, reported further improvements in voice-related distress at 16 weeks but not at 28 weeks on top of standard of care.

Philippa A. Garety
Clementine J. Edwards
Thomas Ward
ResearchOpen Access28 Oct 2024
Nature Medicine

Volume: 30, P: 3658-3668
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
Amendments and CorrectionsOpen Access11 Jul 2023
Nature

Volume: 619, P: E61
Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity

Here, using methylCIBERSORT, the authors characterize the tumour-immune microenvironment of paediatric central nervous system (CNS) tumours and its association with tumour type and prognosis. These findings suggest that immuno-methylomic profiling may inform immunotherapy approaches in paediatric patients with CNS tumour.

Yura Grabovska
Alan Mackay
Daniel Williamson
ResearchOpen Access28 Aug 2020
Nature Communications

Volume: 11, P: 1-15
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth

The mechanisms underlying the activity of non-receptor tyrosine kinase, TNK1, in cancers are unclear. Here the authors show that MARK mediates 14-3-3 and TNK1 interaction which restrains TNK1 activity, while the release of TNK1 from 14-3-3 leads to TNK1 activation through its interaction with ubiquitin and thus results in TNK1-mediated tumor growth in vivo

Tsz-Yin Chan
Christina M. Egbert
Joshua L. Andersen
ResearchOpen Access09 Sept 2021
Nature Communications

Volume: 12, P: 1-17
A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer

Martin J Tymms
Annie YN Ng
Ismail Kola
Research13 Nov 1997
Oncogene

Volume: 15, P: 2449-2462
BIRB-796 is not an effective ABL(T315I) inhibitor

Thomas O'Hare
Brian J. Druker
Correspondence01 Oct 2005
Nature Biotechnology

Volume: 23, P: 1209-1210
A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

M Wagle
A M Eiring
Y Yan
ResearchOpen Access08 Mar 2016
Leukemia

Volume: 30, P: 1493-1501
Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas

H Patterson
S Gill
CS Cooper
Research01 Jun 1994
British Journal of Cancer

Volume: 69, P: 1052-1058
CEREBRAL BLOOD FLOW MEASURED BY NEAR INFRARED SPECTROSCOPY (NIRS) IN CHILDREN UNDERGOING OPEN HEART SURGERY

Penny Fallen
Idris Roberts
A David Edwards
Research01 Feb 1994
Pediatric Research

Volume: 35, P: 259
Using data science to understand the film industry’s gender gap

Dima Kagan
Thomas Chesney
Michael Fire
ResearchOpen Access13 May 2020
Palgrave Communications

Volume: 6, P: 1-16
Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

Activation of the insulin-like growth factor 1 receptor may underlie clinical resistance to inhibition of the anaplastic lymphoma receptor kinase in lung cancer.

Christine M Lovly
Nerina T McDonald
William Pao
Research31 Aug 2014
Nature Medicine

Volume: 20, P: 1027-1034
Pushing the limits of targeted therapy in chronic myeloid leukaemia

Although chronic myeloid leukaemia (CML) can be treated with tyrosine kinase inhibitors (TKIs) against BCR-ABL1, cure is not achieved in most cases. This Review provides an update on resistance to TKIs, and discusses strategies to target BCR-ABL1-independent resistance, which may be necessary to eliminate CML stem cells and advanced disease.

Thomas O'Hare
Matthew S. Zabriskie
Michael W. Deininger
Reviews24 Jul 2012
Nature Reviews Cancer

Volume: 12, P: 513-526
Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations

Kevin Hauser et al. accurately predict the impact of mutations in a kinase on the binding affinities of targeted kinase inhibitors using alchemical free-energy calculations. With 88% accuracy, resistance or sensitivity to therapy is computed for 144 clinically-identified point mutations in this major target in chronic myelogenous leukemia.

Kevin Hauser
Christopher Negron
Lingle Wang
ResearchOpen Access13 Jun 2018
Communications Biology

Volume: 1, P: 1-14
Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling

Y-F Lee
M John
C S Cooper
ResearchOpen Access18 Feb 2003
British Journal of Cancer

Volume: 88, P: 510-515
Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells

Hein Than
Anthony D. Pomicter
Michael W. Deininger
Research24 Jan 2020
Leukemia

Volume: 34, P: 1679-1683
Minimal breast cancer: evaluation of histology and biological marker expression

E A Dublin
R R Millis
L G Bobrow
ResearchOpen Access25 Jun 1999
British Journal of Cancer

Volume: 80, P: 1608-1616
Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting

Thomas Jacob
Anupriya Agarwal
Tania Q. Vu
ResearchOpen Access20 Jun 2016
Scientific Reports

Volume: 6, P: 1-11
MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children

Veronica A Kinsler
Patricia O'Hare
Olga Slater
ResearchOpen Access02 Mar 2017
British Journal of Cancer

Volume: 116, P: 990-993
Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective

Hein Than
Yi Qiao
Michael W. Deininger
Research27 Mar 2018
Leukemia

Volume: 32, P: 2049-2054
Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in Australia

Heather G. Mack
Alexis Ceecee Britten-Jones
Lauren N. Ayton
ResearchOpen Access02 Oct 2022
Gene Therapy

Volume: 30, P: 336-346
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

Ami B. Patel
Anthony D. Pomicter
Michael W. Deininger
Research14 May 2020
Leukemia

Volume: 34, P: 2981-2991
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion

William L. Heaton
Anna V. Senina
Michael W. Deininger
ResearchOpen Access18 Apr 2018
Leukemia

Volume: 32, P: 2399-2411
Patient experiences and perceived value of genetic testing in inherited retinal diseases: a cross-sectional survey

Alexis Ceecee Britten-Jones
Joshua Schultz
Lauren N. Ayton
ResearchOpen Access05 Mar 2024
Scientific Reports

Volume: 14, P: 1-9
The British Prostate Group Autumn Meeting, 20–21 September 1999, Keble College, Oxford

SA McNeill
J Thomas
TB Hargreave
Research Highlights10 May 2000
Prostate Cancer and Prostatic Diseases

Volume: 2, P: 294-299
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib

W Qiang
O Antelope
T O’Hare
Correspondence18 Aug 2017
Leukemia

Volume: 31, P: 2844-2847
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

M S Zabriskie
C A Eide
T O'Hare
CorrespondenceOpen Access19 Nov 2015
Leukemia

Volume: 30, P: 1418-1421
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1

M S Zabriskie
N A Vellore
T O'Hare
Correspondence13 Feb 2015
Leukemia

Volume: 29, P: 1939-1942
Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis

K U Sales
S Friis
T H Bugge
Research27 Jan 2014
Oncogene

Volume: 34, P: 346-356

Search

Filter By:

Search

Quick links